Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

Purpose: Review the state-of-art knowledge of the biology and therapy of chronic
myelogenous leukemia (CML). Experimental Design: A review of the literature was …

Since its introduction less than 3 years ago, imatinib mesylate (STI571) has altered the
entire approach to the therapy of patients with chronic myeloid leukemia (CML). In addition …

Imatinib, a small-molecule ABL kinase inhibitor, is a highly effective therapy for early-phase
chronic myeloid leukaemia (CML), which has constitutively active ABL kinase activity owing …

The deregulated, oncogenic tyrosine kinase Bcr-Abl causes chronic myeloid leukemia
(CML). Imatinib mesylate (Gleevec, STI571), a Bcr-Abl kinase inhibitor, selectively inhibits …

BCR-ABL overexpression and stem cell quiescence supposedly contribute to the failure of
imatinib mesylate (IM) to eradicate chronic myeloid leukemia (CML). However, BCR-ABL …

Purpose: Chronic myeloid leukemia (CML) is effectively treated with imatinib. However,
reactivation of Bcr-Abl via kinase domain mutations that reduce sensitivity to imatinib can …

Chronic myeloid leukemia (CML) starts with the acquisition of a BCR-ABL fusion gene in a
single hematopoietic stem cell, but the time to progression is unpredictable. Although the …

Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic
myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most …